Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates ...

The classification of AML is based on the French-American-British system in which morphologic and immunophenotypic features of blast cells divide AML into 8 distinct subtypes labeled M0-M7. M3 is the ...

Omeros Corp. has successfully completed its initial study in nonhuman primates evaluating the efficacy and safety of its Oncotox-AML cancer therapeutic platform for acute myeloid leukemia (AML).

The MarketWatch News Department was not involved in the creation of this content. -- ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 ...

Examining protein changes in peripheral blood cells just 24 hours after initiating chemotherapy for acute myeloid leukemia (AML) could predict 5-year overall survival, potentially allowing treatment ...

Multi-hit TP53 mutations are linked to poor survival in both MPN and AML, with median OS ranging from 4.8 to 11.6 months. Factors such as ASCT, pre-transplant therapy response, and concurrent TET2 or ...

SEATTLE, WA / ACCESS Newswire / June 18, 2025 / Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO), a clinical-stage biotechnology company developing novel bispecific immuno-oncology therapeutics based on ...

ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...